250 related articles for article (PubMed ID: 20935224)
1. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
Delgado DC; Hank JA; Kolesar J; Lorentzen D; Gan J; Seo S; Kim K; Shusterman S; Gillies SD; Reisfeld RA; Yang R; Gadbaw B; DeSantes KB; London WB; Seeger RC; Maris JM; Sondel PM
Cancer Res; 2010 Dec; 70(23):9554-61. PubMed ID: 20935224
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
Erbe AK; Wang W; Carmichael L; Kim K; Mendonça EA; Song Y; Hess D; Reville PK; London WB; Naranjo A; Hank JA; Diccianni MB; Reisfeld RA; Gillies SD; Matthay KK; Cohn SL; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Gilman AL; Yu AL; Sondel PM
Clin Cancer Res; 2018 Jan; 24(1):189-196. PubMed ID: 28972044
[No Abstract] [Full Text] [Related]
3. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.
Venstrom JM; Zheng J; Noor N; Danis KE; Yeh AW; Cheung IY; Dupont B; O'Reilly RJ; Cheung NK; Hsu KC
Clin Cancer Res; 2009 Dec; 15(23):7330-4. PubMed ID: 19934297
[TBL] [Abstract][Full Text] [Related]
4. KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.
Erbe AK; Diccianni MB; Mody R; Naranjo A; Zhang FF; Birstler J; Kim K; Feils AS; Hung JT; London WB; Shulkin BL; Mathew V; Parisi MT; Servaes S; Asgharzadeh S; Maris JM; Park J; Yu AL; Sondel PM; Bagatell R
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822669
[TBL] [Abstract][Full Text] [Related]
5. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
Wang W; Erbe AK; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Weiss JM; Mier J; Panka D; McDermott DF; Sondel PM
Cancer Immunol Immunother; 2016 Dec; 65(12):1523-1532. PubMed ID: 27695964
[TBL] [Abstract][Full Text] [Related]
6. Human Leukocyte Antigen-C Genotype and Killer Immunoglobulin-like Receptor-Ligand Matching in Korean Living Donor Liver Transplantation.
Lee H; Park KH; Park HS; Ryu JH; Lim J; Kim Y; Na GH; Kim DG; Oh EJ
Ann Lab Med; 2017 Jan; 37(1):45-52. PubMed ID: 27834065
[TBL] [Abstract][Full Text] [Related]
7. Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.
Keating SE; Ní Chorcora C; Dring MM; Stallings RL; O'Meara A; Gardiner CM
Tissue Antigens; 2015 Sep; 86(3):172-7. PubMed ID: 26202659
[TBL] [Abstract][Full Text] [Related]
8. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
[TBL] [Abstract][Full Text] [Related]
9. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
Erbe AK; Wang W; Carmichael L; Hoefges A; Grzywacz B; Reville PK; Ranheim EA; Hank JA; Kim K; Seo S; Mendonca EA; Song Y; Kenkre VP; Hong F; Gascoyne RD; Paietta E; Horning SJ; Miller JS; Kahl B; Sondel PM
J Immunother Cancer; 2019 Mar; 7(1):70. PubMed ID: 30871628
[TBL] [Abstract][Full Text] [Related]
10. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
[TBL] [Abstract][Full Text] [Related]
12. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.
Forlenza CJ; Boudreau JE; Zheng J; Le Luduec JB; Chamberlain E; Heller G; Cheung NK; Hsu KC
J Clin Oncol; 2016 Jul; 34(21):2443-51. PubMed ID: 27069083
[TBL] [Abstract][Full Text] [Related]
13. Impact of incompatible killer cell immunoglobulin-like receptor and its ligand on the outcome of haploidentical bone marrow transplantation.
Duan LN; Han HX; Liu J; Yan HM; Zhu L; Xue M; Ding L; Zhu PY; Wang HX; Ji SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):809-15. PubMed ID: 17708809
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
Hank JA; Gan J; Ryu H; Ostendorf A; Stauder MC; Sternberg A; Albertini M; Lo KM; Gillies SD; Eickhoff J; Sondel PM
Clin Cancer Res; 2009 Sep; 15(18):5923-30. PubMed ID: 19737959
[TBL] [Abstract][Full Text] [Related]
15. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.
Feils AS; Erbe AK; Birstler J; Kim K; Hoch U; Currie SL; Nguyen T; Yu D; Siefker-Radtke AO; Tannir N; Tolaney SM; Diab A; Sondel PM
Cancer Immunol Immunother; 2023 Jul; 72(7):2099-2111. PubMed ID: 36823323
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.
Shusterman S; London WB; Gillies SD; Hank JA; Voss SD; Seeger RC; Reynolds CP; Kimball J; Albertini MR; Wagner B; Gan J; Eickhoff J; DeSantes KB; Cohn SL; Hecht T; Gadbaw B; Reisfeld RA; Maris JM; Sondel PM
J Clin Oncol; 2010 Nov; 28(33):4969-75. PubMed ID: 20921469
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Killer Immunoglobulin-like Receptor (KIR) and HLA Genotypes to Predict the Occurrence of Acute Allograft Rejection after Kidney Transplantation.
Jafari D; Nafar M; Yekaninejad MS; Abdolvahabi R; Lesan Pezeshki M; Razaghi E; Amirzargar AA
Iran J Allergy Asthma Immunol; 2017 Jun; 16(3):245-255. PubMed ID: 28732438
[TBL] [Abstract][Full Text] [Related]
18. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.
Pérez-Martínez A; Leung W; Muñoz E; Iyengar R; Ramírez M; Vicario JL; Lassaletta A; Sevilla J; González-Vicent M; Madero L; Díaz-Pérez MA
Pediatr Blood Cancer; 2009 Jul; 53(1):120-4. PubMed ID: 19215002
[TBL] [Abstract][Full Text] [Related]
19. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.
Yu J; Heller G; Chewning J; Kim S; Yokoyama WM; Hsu KC
J Immunol; 2007 Nov; 179(9):5977-89. PubMed ID: 17947671
[TBL] [Abstract][Full Text] [Related]
20. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.
Koehn TA; Trimble LL; Alderson KL; Erbe AK; McDowell KA; Grzywacz B; Hank JA; Sondel PM
Front Pharmacol; 2012; 3():91. PubMed ID: 22623917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]